Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542616 · ClinicalTrials.gov registry record · NA
Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma
A NA study of Glaucoma, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04542616: Completed NA study of Glaucoma, sponsored by State University of New York at Buffalo.
NCT04542616 is a NA study of Glaucoma that has completed, run by State University of New York at Buffalo. The registered enrollment target is 80 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04542616, a NA study of Glaucoma, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.
Primary Outcome
Mean IOP in each treatment group at the above time points
Conditions Studied
Interventions
- DEVICE Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation
Study Locations (1)
New York
- The Ira G. Ross Eye Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
What the finished NCT04542616 record still lists
NCT04542616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation is the first listed.
NCT04542616 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04542616 about?
NCT04542616 is a clinical study titled "Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma". To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.
What is the current status of trial NCT04542616?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2020-08-13. Estimated completion is 2024-07-31.
What conditions does trial NCT04542616 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT04542616?
The interventions under investigation include: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation (DEVICE).
Who is sponsoring clinical trial NCT04542616?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04542616 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04542616's enrollment target sits among peer trials
80 50th of 92 higher than 43 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI